| Kayla Anne Spearman, MA, CF-SLP | |
|
2255 S Burnside Ave, Gonzales, LA 70737-4642 | |
| (225) 269-9971 | |
| Not Available |
| Full Name | Kayla Anne Spearman |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 2255 S Burnside Ave, Gonzales, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033978374 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 9460 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kayla Anne Spearman, MA, CF-SLP 2255 S Burnside Ave, Gonzales, LA 70737-4642 Ph: (225) 269-9971 | Kayla Anne Spearman, MA, CF-SLP 2255 S Burnside Ave, Gonzales, LA 70737-4642 Ph: (225) 269-9971 |
News Archive
Researchers at Mayo Clinic in Florida, the University of Florida in Gainesville, and the Institute for Systems Biology in Seattle have received a $7.5 million grant from the National Institutes of Health to take a new and more expanded approach to identifying drug targets to treat and possibly prevent Alzheimer's disease.
When an employee told a group of 20-somethings they needed face masks to enter his fast-food restaurant, one woman fired off a stream of expletives. "Isn't this Orange County?" snapped a man in the group. "We don't have to wear masks!"
Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).
Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent. In a report in the January 17 issue of The Lancet, an international research team reports that a protocol adding lapatinib (Tykerb) to trastuzumab (Herceptin) was more effective than single-drug treatment with either drug in eliminating microscopic signs of cancer at the time the tumors were surgically removed.
› Verified 5 days ago
Gabrielle Alexis Gutierrez, M.S. CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 821 N Burnside Ave, Gonzales, LA 70737 Phone: 225-939-7205 | |
Auldyn Marie Leblanc, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 40140 River Winds Ct, Gonzales, LA 70737 Phone: 225-313-8289 | |
Jenna V Dreher, MS, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2255 S Burnside Ave, Gonzales, LA 70737 Phone: 225-269-9971 | |
Williamson Speech Therapy And Learning Center Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 625 S Burnside Ave Ste 2, Gonzales, LA 70737 Phone: 225-437-9535 Fax: 225-647-3704 | |
Samantha Kay Fleniken, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2255 S Burnside Ave, Gonzales, LA 70737 Phone: 225-269-9971 | |
Lorie P Hebert, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 821 N Burnside Ave, Gonzales, LA 70737 Phone: 225-939-7205 |